Nearly 4,000 people in the US are waiting for heart transplants. And on average, it takes about six months to get one, during which time some patients will die.
So researchers have been trying for decades to make an artificial heart that can be permanently implanted. But building one that imitates a real heart over a long period of time without breaking or causing infections or blood clots is incredibly difficult. One problem is that the more parts there are, the more things could go wrong.
To solve the problem, Sanjiv Kaul and his team at Oregon Health and Science University are developing an artificial heart with an extremely simple design—it contains a single moving piece with no valves. They believe it could be the first such device that could last the rest of a person’s life.
Originally designed by Richard Wampler, OHSU’s artificial heart creates a blood flow that mimics a natural pulse. It replaces the human heart’s two lower chambers, the ventricles, with a titanium tube containing a hollow rod that moves back and forth. This back-and-forth motion pushes blood to the lungs so it can extract oxygen and then move the oxygenated blood through the rest of the body.
Kaul hopes the simple design will overcome the limitations of previous artificial hearts.
The first artificial heart, AbioCor, got limited approval from the US Food and Drug Administration in 2006. It was implanted in just 15 people and is no longer available. About the size of a grapefruit, it was too large to fit in children and many women.
Only one artificial heart, made by SynCardia, is currently available in the US. It’s meant to be a temporary fix while patients wait for a heart transplant. It requires people to carry around an external air compressor in a backpack that pumps the implanted artificial heart from the outside.
Other companies, like Cleveland Heart and French firm Carmat, have also been trying to build a fully artificial heart. Last year, Swiss researchers reported that they had 3-D-printed one, but it started to degrade after only 45 minutes.
Kaul and his team tested an early prototype of their artificial heart in cows and didn’t notice any problems or side effects. Next, they’re planning to test a smaller version—small enough to fit in children as young as 10—in sheep for about three months.
“If it works for that long, we think we’ll be able to put it in people,” he says.
Kaul thinks the device could be available to patients in five years or even perhaps even sooner.
OHSU’s artificial heart will probably need to be charged with a small, hand-held battery pack outside the body. But the hope is that a smaller, more efficient battery could eventually be implanted under the skin and be recharged from the outside.
Biotechnology and health
What to know about this autumn’s covid vaccines
New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.
A biotech company says it put dopamine-making cells into people’s brains
The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.
Tiny faux organs could crack the mystery of menstruation
Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.
How AI can help us understand how cells work—and help cure diseases
A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.